|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
BJ-TSA-9, a novel human tumor-specific gene, has potential as a biomarker of lung cancer.
|
16354590 |
2005 |
|
Adenocarcinoma of lung (disorder)
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
BJ-TSA-9 mRNA was expressed in 52.5% (21 of 40) of human lung cancer tissues and was especially higher in lung adenocarcinoma (68.8%).
|
16354590 |
2005 |
|
Lung Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
BJ-TSA-9, a novel human tumor-specific gene, has potential as a biomarker of lung cancer.
|
16354590 |
2005 |
|
Malignant neoplasm of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, BJ-TSA-9 may serve as a marker for lung cancer diagnosis and as a marker, in combination with two other tumor markers, for the prediction of the recurrence and prognosis of lung cancer patients.
|
16354590 |
2005 |
|
Carcinoma of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, BJ-TSA-9 may serve as a marker for lung cancer diagnosis and as a marker, in combination with two other tumor markers, for the prediction of the recurrence and prognosis of lung cancer patients.
|
16354590 |
2005 |
|
Primary malignant neoplasm of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, BJ-TSA-9 may serve as a marker for lung cancer diagnosis and as a marker, in combination with two other tumor markers, for the prediction of the recurrence and prognosis of lung cancer patients.
|
16354590 |
2005 |
|
Lung Neoplasms
|
0.020 |
Biomarker
|
group |
LHGDN |
Detection of circulating cancer cells in lung cancer patients with a panel of marker genes.
|
18514066 |
2008 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Using a screen to measure reversion of malignant cells into phenotypically nonmalignant cells in 3D gels, we identified FAM83A as a candidate cancer-associated gene capable of conferring resistance to EGFR-TKIs.
|
22886303 |
2012 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
FAM83A overexpression in cancer cells increased proliferation and invasion and imparted EGFR-TKI resistance both in cultured cells and in animals.
|
22886303 |
2012 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Using a screen to measure reversion of malignant cells into phenotypically nonmalignant cells in 3D gels, we identified FAM83A as a candidate cancer-associated gene capable of conferring resistance to EGFR-TKIs.
|
22886303 |
2012 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Analyses of published clinical data revealed a correlation between high FAM83A expression and breast cancer patients' poor prognosis.
|
22886303 |
2012 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Analyses of published clinical data revealed a correlation between high FAM83A expression and breast cancer patients' poor prognosis.
|
22886303 |
2012 |
|
Adenocarcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
The 20 genes such as SPP1, SPINK1, and FAM83A with largest fold changes in smokers also showed similar large and highly significant fold changes in nonsmokers and vice versa, showing commonalities in expression changes for adenocarcinomas in both smokers and nonsmokers for these genes.
|
26081616 |
2015 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Here, we find that FAM83A expression is elevated in 36% of HER2+ BC tumors.
|
28463969 |
2017 |
|
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
We assessed transcriptional expression patterns of eight FAM83 family genes (FAM83A-H) across tumor types, the relationship between their expression and changes in DNA copy number, and the association with patient survival.
|
28078827 |
2017 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Importantly, the FAM83A locus was amplified in a number of human cancers and silencing FAM83A in associated cancer cell lines inhibited activation of the WNT/β-catenin and TGF-β signaling pathways and reduced tumorigenicity.
|
28287611 |
2017 |
|
Malignant neoplasm of pancreas
|
0.020 |
Biomarker
|
disease |
BEFREE |
Overexpression of FAM83A markedly promoted, whereas inhibition of FAM83A decreased, CSC-like traits and chemoresistance both in vitro and in an in vivo mouse model of pancreatic cancer.
|
28287611 |
2017 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Importantly, the FAM83A locus was amplified in a number of human cancers and silencing FAM83A in associated cancer cell lines inhibited activation of the WNT/β-catenin and TGF-β signaling pathways and reduced tumorigenicity.
|
28287611 |
2017 |
|
Pancreatic carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overexpression of FAM83A markedly promoted, whereas inhibition of FAM83A decreased, CSC-like traits and chemoresistance both in vitro and in an in vivo mouse model of pancreatic cancer.
|
28287611 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
The results indicated that TSGP exhibited a protective effect against NAFLD and the underlying mechanism may involve augmentation of anti-lipid peroxidation capacity via regulation of PPARα and CYP2E1-mediated pathways.
|
29201200 |
2017 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
The correlation analysis revealed that advanced stage tumors (stage III-IV) had higher FAM83A expression than early stage tumors (stage I-II) (P= 0.004).
|
31594212 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Lastly, Cox multivariate survival analysis showed that FAM83A differential expression level (low vs. high) was the only independent factor predicting the prognosis of LUAD patients (P=0.001).
|
31175804 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry analysis on 86 paraffin samples further demonstrated that the LUAD tissue had higher FAM83A expression than adjacent lung tissue (P< 0.001).
|
31594212 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.040 |
Biomarker
|
disease |
BEFREE |
Of note, FAM83A has potential significance in drug resistance, and may present a candidate biomarker for the prognosis and treatment of patients with LUAD.
|
31065463 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Family with sequence similarity 83, member A (FAM83A), as a potential tumor promoter, was reported to contribute to the progression of several malignant tumors.
|
31444970 |
2019 |